Encyclopedia
List of AM cannabinoids
Alexandros Makriyannis is a professor in the Department of Medicinal Chemistry at Northeastern University, where his research group has synthesized many new compounds with cannabinoid activity. Some of those are:
| Name | Class | Ki / nM at CB1 | Ki / nM at CB2 | Selectivity | CLogP | Structure | Description |
|---|---|---|---|---|---|---|---|
| AM-087 | Dibenzopyran | 0.43 | 6.47 | An analgesic CB1 agonist derived from Δ8-THC substituted with a side chain on the 3-position, roughly 100 times as potent as THC. | |||
| AM-251 | Pyrazole derivative | 7.5 | 7.08 | An inverse agonist at the CB1 cannabinoid receptor that is structurally related to SR141716A (rimonabant), but has a higher binding affinity. | |||
| AM-279 | A Schedule I substance in Alabama. | ||||||
| AM-281 | N-(morpholin-4-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide | ||||||
| AM-356 | 17.9 | 868 | 5.55 | A synthetically created stable chiral analog of anandamide, it acts on both cannabinoid receptors. | |||
| AM-374 | Palmitylsulfonyl fluoride | ||||||
| AM-381 | Stearylsulfonyl fluoride | ||||||
| AM-404 | 7.02 | An active metabolite of paracetamol (acetaminophen) and a likely inhibitor of fatty acid amide hydrolase (FAAH) | |||||
| AM-411 | 6.80 | 52.0 | An adamantyl-substituted derivative of Δ8-THC, it is a potent and fairly selective CB1 full agonist and a moderately potent CB2 agonist. | ||||
| AM-630 | 32.1 | CB2 (165×) | 4.19 | A potent and selective inverse agonist for the cannabinoid receptor CB2 and a weak partial agonist at CB1. | |||
| AM-661 | 1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole | ||||||
| AM-678 | 9.00 ± 5.00 | 2.94 ± 2.65 | CB2 | 5.68 | Another name for JWH-018, it is a full agonist at both cannabinoid receptors with some selectivity for CB2. | ||
| AM-679 | 13.5 | 49.5 | 6.04 | An iodobenzoylindole which acts as a moderately potent agonist for both cannabinoid receptors. | |||
| AM-694 | 0.08 | 1.44 | CB1 (18×) | 5.54 | An iodobenzoylindole which acts as a potent and selective agonist for the CB1 cannabinoid receptor. | ||
| AM-735 | 8.9 | 7.4 | 3-bornyl-Δ8-THC, a mixed CB1 / CB2 agonist. | ||||
| AM-855 | 22.3 | 58.6 | CB1 | 7.1 | An analgesic derivative of Δ8-tetrahydrocannabinol, it is an agonist at both CB1 and CB2 with moderate selectivity for CB1. | ||
| AM-881 | 5.3 | 95 | A chlorine-substituted stereoisomer of anandamide. | ||||
| AM-883 | 9.9 | 226 | An allyl-substituted stereoisomer of anandamide. | ||||
| AM-905 | 1.2 | 5.3 | CB1 | 4.98 | A potent and reasonably selective agonist for the CB1 cannabinoid receptor. | ||
| AM-906 | 0.8 | 9.5 | CB1 | 4.98 | A potent and dodecally selective agonist for the CB1 cannabinoid receptor. | ||
| AM-919 | 2.2 | 3.4 | CB1 | 6.21 | A potent agonist at both CB1 and CB2 with moderate selectivity for CB1. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | ||
| AM-926 | 2.2 | 4.3 | CB1 | A potent agonist at both CB1 and CB2 with moderate selectivity for CB1. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | |||
| AM-938 | 1.2 | 0.3 | CB2 (4×) | 5.92 | A potent agonist at both CB1 and CB2. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | ||
| AM-1116 | 7.4 | A dimethylated stereoisomer of anandamide. | |||||
| AM-1172 | An endocannabinoid analog specifically designed to be a potent and selective inhibitor of AEA uptake that is resistant to FAAH hydrolysis. | ||||||
| AM-1220 | 3.88 | 73.4 | CB1 (19×) | 4.73 | A potent and selective analgesic CB1 agonist (as racemate). The (R) enantiomer has around 1000× higher affinity for CB1 than (S) enantiomer. | ||
| AM-1221 | 52.3 | 0.28 | CB2 (187×) | A potent and selective CB2 agonist. | |||
| AM-1235 | 1.5 | 20.4 | CB1 (13×) | A moderately CB1 selective agonist. | |||
| AM-1241 | 3.4 | CB2 (80×) | A potent and selective analgesic CB2 agonist. | ||||
| AM-1248 | CB1 | A moderately potent agonist with some selectivity for CB1, containing an unusual 3-(adamant-1-oyl) substitution on the indole ring. | |||||
| AM-1710 | Cannabilactone | CB2 (54×) | A CB2 selective cannabilactone. Acts as a dual CB2 agonist / CB1 antagonist. | ||||
| AM-1714 | Cannabilactone | CB2 (490×) | 6.17 | A CB2 selective cannabilactone. | |||
| AM-1902 | A nonclassical cannabinoid | ||||||
| AM-2201 | 1.0 | 2.6 | CB1 | 5.18 | A potent agonist at both CB1 and CB2 with moderate selectivity for CB1. | ||
| AM-2212 | 1.4 | 18.9 | CB1 | A potent agonist at both CB1 and CB2 with dodecal selectivity for CB1. | |||
| AM-2213 | 3.0 | 30 | CB1 (10×) | A potent agonist at both CB1 and CB2. | |||
| AM-2232 | 0.28 | 1.48 | 4.75 | A potent agonist at both CB1 and CB2. | |||
| AM-2233 | 1.8 | 2.2 | CB1 | 5.09 | The (R) enantiomer is potent and selective CB1 agonist used in 131I radiolabelled form to map distribution of CB1 receptors in brain. | ||
| AM-2389 | 0.16 | CB1 (26×) | 6 | Classical cannabinoid derivative. | |||
| AM-3102 | 33000 | 26000 | An analog of oleoylethanolamide, the endogenous agonist for proliferator-activated receptor α (PPARα). It also acts as a weak cannabinoid agonist. | ||||
| AM-4030 | 0.7 | 8.6 | CB1 (12×) | 6.17 | A potent agonist at both CB1 and CB2, it is dodecally selective for CB1. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | ||
| AM-4054 | 2.2 | CB1 (40×) | A potent but slow-onset agonist. | ||||
| AM-4056 | 0.041 | 6.51 | Another name for HU-243, it is a potent agonist at both the CB1 and CB2 receptors. | ||||
| AM-4113 | CB1 | A CB1 selective neutral antagonist. | |||||
| AM-6545 | CB1 | 4.06 | A peripherally selective silent antagonist of CB1 receptors. | ||||
| AM-7438 | A potent agonist of CB1 and CB2 with reduced duration of action. | ||||||
| AM-11245 |
Sources and credits
This article is adapted from the Wikipedia article “List of AM cannabinoids”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.